Melanomas that contain mutations in the BRAF gene may be treated with drugs that target the dysfunctional BRAF protein. For melanomas that do not have mutated BRAF, it may be necessary to block two other molecular pathways during treatment: the MAP kinase pathway and the PI3 kinase/AKT pathway. In this study, researchers are evaluating the safety and effectiveness of giving two drugs that target these pathways in patients with melanoma that does not contain mutated BRAF. The two drugs are trametinib and GSK2141795.
Trametinib is already approved for treating advanced melanoma with a BRAF mutation. It works by blocking MEK, a protein in the MAP kinase pathway. GSK2141795 is an investigational drug designed to inhibit cancer growth by blocking the activity of the AKT protein. Both drugs are taken orally (by mouth).